TransUnion heads into the back half of May under mounting pressure — a sharp 15% one-month slide, a cluster of coordinated insider selling, and a Street that keeps lowering the bar.
The most striking development this week was at the executive level. On May 18, six senior insiders sold simultaneously — the CEO Christopher Cartwright offloaded 26,284 shares worth roughly $1.8 million, the CFO Todd Cello sold 18,253 shares for $1.25 million, and four other C-suite and divisional presidents sold in the same session. The sales came just days after a round of equity awards on May 12, a common pattern following vesting, but the breadth of the cluster is hard to ignore. Combined with a stock already down 16% year-to-date, the optics are difficult for would-be buyers.
Short interest has quietly been building this week, though it remains in unremarkable territory. The SI % of free float has edged up to roughly 5%, with shares short rising about 8% over the past seven days to reach 9.5 million. That's a meaningful weekly move, but the absolute level keeps TransUnion well outside the heavily-shorted camp. Borrow is essentially free at 0.56% APR — a level unchanged in any meaningful way for months. Availability is ample at 486% of short interest, meaning there are nearly five shares available to borrow for every one already shorted. The lending market is not under any stress, and the rising SI looks more like incremental hedging than a conviction short. Options positioning reinforces that read: the put/call ratio of 0.34 is running slightly below its 20-day average and well away from defensive territory, with a z-score near zero. Options traders are not positioning for a sharp drop.
The Street tells the more sobering story. B of A Securities trimmed its target to $80 yesterday, reiterating Neutral — fresh pressure from a bellwether name just as the stock hit a new recent low. JPMorgan held Overweight on April 29 but cut from $95 to $90. Needham stood firm at a $95 Buy on the same day. The mean target now runs at $91, implying roughly 38% upside from current levels — a wide gap that reflects how far the stock has de-rated rather than fresh conviction in a rebound. Morgan Stanley's most recent action was a target cut to $100 in March, keeping Overweight; Goldman's last move was a trim to $80 in February on a Neutral. The direction of travel is clear: even bulls are scaling back. The P/E multiple has contracted about 16% over 30 days to 13x, and EV/EBITDA has slipped below 9.1x — both tracking the stock's descent. The bear case — credit inquiry pressure in a weaker macro environment, high debt, a potential squeeze on P/E multiples toward 12x — looks increasingly live given the macro backdrop. The bull case of M&A-driven growth and a discount to historical multiples is still structurally intact, but investors have not rewarded it.
The peer picture adds context. The closest comparable, EFX, fell about 3.6% on the week — directionally aligned with TransUnion but less severe. SSNC was off less than 1%. Meanwhile ALIT surged 21% and PCTY climbed 10%, highlighting that the selling is company-specific rather than a broad sector rotation. TransUnion is losing ground even in weeks where data services peers are recovering.
Recent earnings reactions have consistently gone against the stock. Q1 results released May 12 triggered a near 5% one-day drop and a further 5.6% slide over the following week. The prior print on April 28 fell 1% the next day and 4.1% over five sessions. Both reads point to the same pattern: the stock struggles to hold its footing around earnings. The next event is scheduled for July 24, which gives several weeks for the current pressure to either stabilise or deepen. The key question between now and then is whether macro data on consumer credit — particularly mortgage originations where TransUnion's VantageScore adoption is in focus — turns enough to stabilise analyst estimates before another print.
See the live data behind this article on ORTEX.
Open TRU on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
